Page 174

152. Samkoff LM, Daras M, Tuchman AJ, Koppel BS. 1997. Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology.; 49: 304-5.

153. Schapiro RT. 1999. Medications used in the treatment of multiple sclerosis. Phys Med Rehabil Clin N Am.; 10: 437-46, ix.

154. Schiffer RB, Caine ED. 1991. The interaction between depressive affective disorder and neuropsychological test performance in multiple sclerosis patients. J Neuropsychiatry Clin Neurosci.; 3: 28-32.

155. Schiffer RB, Wineman NM. 1990. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry.; 147: 1493-7.

156. Scott TF, Allen D, Price TR, McConnell H, Lang D. 1996. Characterization of major depression symptoms in multiple sclerosis patients. J Neuropsychiatry Clin Neurosci.; 8: 318-23.

157. Scott TF, Nussbaum P, McConnell H, Brill P. 1995. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res.; 17: 421-2.

158. Sipski ML. 2000. The neurologic basis for sexual arousal and orgasm: effects of spinal cord injury. Ann Neurol.

159. Sipski ML, Alexander CJ. 1993. Sexual activities, response and satisfaction in women pre- and post-spinal cord injury. Arch Phys Med Rehabil.; 74: 1025-9.

160. Sipski ML, Alexander CJ, Rosen RC. 1999. Sexual response in women with spinal cord injuries: implications for our understanding of the able bodied. J Sex Marital Ther.; 25: 11-22.

161. Sipski ML, Rosen RC, Alexander CJ, Hamer RM. 2000. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology.; 55: 812-5.

162. Smith SJ, Young CA. 2000. The role of affect on the perception of disability in multiple sclerosis. Clin Rehabil.; 14: 50-4.

163. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. 1990. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol.; 28: 512-5.

164. Solaro C, Lunardi GL, Capello E, et al. 1998. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology.; 51: 609-11.

165. Spissu A, Cannas A, Ferrigno P, Pelaghi AE, Spissu M. 1999. Anatomic correlates of painful tonic spasms in multiple sclerosis. Movement Disord.; 14: 331-5.

166. Staerman F, Guiraud P, Coeurdacier P, Menard D, Edan G, Lobel B. 1996. Value of nocturnal penile tumescence and rigidity (NPTR) recording in impotent patients with multiple sclerosis. Int J Impot Res.; 8: 241-5.

167. Starck M, Albrecht H, Pollmann W, Straube A, Dieterich M. 1997. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol.; 244: 9-16.

168. Stenager EN, Koch-Henriksen N, Stenager E. 1996. Risk factors for suicide in multiple sclerosis. Psychother Psychosom.; 65: 86-90.

169. Stenager EN, Stenager E. 1992. Suicide and patients with neurologic diseases. Methodologic problems. Arch Neurol.; 49: 1296-303.

170. Stenager E, Knudsen L, Jensen K. 1991. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand.; 84: 197-200.

171. Stolp-Smith KA, Carter JL, Rohe DE, Knowland DP 3rd. 1997. Management of impairment, disability, and handicap due to multiple sclerosis. Mayo Clin Proc.; 72: 1184-96.

172. Tanaka M, Cummins TR, Ishikawa K, Dib-Hajj SD, Black JA, Waxman SG. 1998. SNS Na+ channel expression increases in dorsal root ganglion neurons in the carrageenan inflammatory pain model. Neuroreport.; 9: 967-72.

173. Taylor A, Taylor RS. 1998. Neuropsychologic aspects of multiple sclerosis. Phys Med Rehabil Clin N Am.; 9: 643-57, vii-viii.

174. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. 1995. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology.; 45: 1277-85.